1. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein
- Author
-
Xiaodong Luan, Yong Zhao, Shuyang Zhang, Yiyang Wang, Ruilin Zhou, Zhuang Tian, Ying Xiao, Zhiyu Zhang, Meixi Liu, Hui Wang, Yifei Wang, and Siqin Feng
- Subjects
0301 basic medicine ,Models, Molecular ,TSA, thermo shift assay ,Pharmacology ,Benzoates ,chemistry.chemical_compound ,media_common ,chemistry.chemical_classification ,Drug discovery ,Protein Stability ,Homology Modeling ,RBD, receptor-binding domain ,Transmembrane protein ,N, nucleocapsid protein ,Drug repositioning ,Infectious Diseases ,Hydrazines ,Drug development ,Severe acute respiratory syndrome-related coronavirus ,Spike Glycoprotein, Coronavirus ,Virtual drug design ,Angiotensin-Converting Enzyme 2 ,Algorithms ,Protein Binding ,Drug ,Microbiology (medical) ,S, spike ,media_common.quotation_subject ,KD, equilibrium dissociation constant ,030106 microbiology ,Eltrombopag ,koff, dissociation rate ,SPR, surface plasmon resonance ,Biology ,kon, association rate ,ACE2, angiotensin-converting enzyme 2 ,Microbiology ,Article ,03 medical and health sciences ,Structure-Activity Relationship ,E, envelope protein ,Surface plasmon resonance ,Genetics ,Humans ,Computer Simulation ,Homology modeling ,Molecular Biology ,Ecology, Evolution, Behavior and Systematics ,SARS-CoV-2 ,Drug Repositioning ,030104 developmental biology ,chemistry ,M, membrane protein ,Drug Design ,RU, resonance unit ,Pyrazoles ,Glycoprotein ,SARS-CoV-2, severe acute respiratory syndrome coronavirus-2 - Abstract
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a current global threat for which there is an urgent need to search for an effective therapy. The transmembrane spike (S) glycoprotein of SARS-CoV-2 directly binds to the host angiotensin-converting enzyme 2 (ACE2) and mediates viral entrance, which is therefore considered as a promising drug target. Considering that new drug development is a time-consuming process, drug repositioning may facilitate rapid drug discovery dealing with sudden infectious diseases. Here, we compared the differences between the virtual structural proteins of SARS-CoV-2 and SARS-CoV, and selected a pocket mainly localizing in the fusion cores of S2 domain for drug screening. A virtual drug design algorithm screened the Food and Drug Administration-approved drug library of 1234 compounds, and 13 top scored compounds were obtained through manual screening. Through in vitro molecular interaction experiments, eltrombopag was further verified to possess a high binding affinity to S protein plus human ACE2 and could potentially affect the stability of the ACE2-S protein complex. Hence, it is worth further exploring eltrombopag as a potential drug for the treatment of SARS-CoV-2 infection., Graphical abstract Unlabelled Image, Highlights • Compare the differences between the structural proteins of SARS-CoV-2 and SARS-CoV. • Screen approved drugs via virtual drug design algorithm based on S2 domain pocket. • Surface plasmon resonance and Thermo Shift Assay are established for validation. • Eltrombopag showed a high binding affinity to spike protein and ACE2. • Provide a novel and rapid way to screen potent drugs during the pandemic.
- Published
- 2020